ALISO VIEJO, Calif.--(BUSINESS WIRE)--

Ambry Genetics, the worldwide leader in hereditary cancer testing, announced today that it has filed an antitrust counterclaim against Myriad Genetics in response to the patent infringement lawsuit Myriad and other plaintiffs filed against Ambry on July 9, 2013, University of Utah Research Foundation, et al, v. Ambry Genetics Corporation, United States District for the District of Utah, Case No. 2:13-cv-00640-RJS.

Ambry's antitrust counterclaim alleges that:

Ambry Genetics was the first commercial laboratory to launch hereditary cancer panels using next generation sequencing in 2012 with their comprehensive BreastNext, OvaNext, ColoNext and CancerNext products. With hundreds of clinics and institutions utilizing these panels, Ambry has established itself as the scientific leaders in inherited cancer panel testing. Following the Supreme Courts landmark June 13, 2013 decision in AMP et al v. Myriad Genetics, et al., Ambry included BRCA1 and BRCA2 diagnostic testing to its suite of panels.

Being sued for patent infringement a month after the Supreme Court ruled 9-0 unanimously against Myriad is just wrong, said Chief Executive Officer, Charles Dunlop. As alleged in our counterclaim, Myriad Genetics is also wrongfully depicting Ambrys variants of unknown significance (VUS) statistic to be as high as 30% when it actually is approximately 5% for BRCA1/2 diagnostic testing. Tactics like this have no place in the medical field, especially cancer, as it will take a collaborative, industry wide effort to further understand the disease and find cures.

About Ambry Genetics

Ambry Genetics is a College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified commercial clinical laboratory with headquarters in Orange County, California. Since its founding in 1999, it has become a leader in providing genetic services focused on clinical diagnostics and genomic services, particularly in sequencing and array services. Ambry has established a reputation for unparalleled service and for over a decade has been at the forefront of applying new technologies to the clinical molecular diagnostics market and to the advancement of disease research. To learn more about testing and services available through Ambry Genetics, visit http://www.ambrygen.com.

Read more from the original source:
Ambry Genetics Sues Myriad Genetics for Violating Federal Antitrust Laws

Comments are closed.